医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

GC Pharma Reports Full Year 2021 Results

2022年02月14日 PM07:30
このエントリーをはてなブックマークに追加


 

YONGIN, South Korea

GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited consolidated financial results for the year ended 31 December 2021.

Key Figures

Full Year 2021

Growth(1)

Total revenues

KRW 1,537.8 billion

2.2%

Operating Income

KRW 73.7 billion

46.6%

Net Income

KRW 136.9 billion

53.4%

(1) Results and percentages compare to full financial year 2020

Financial Highlights

  • Delivered total revenue growth of 2.2% YoY to KRW 1,537.8 billion (2020: 1,504.1 billion), and operating profit increased 46.6% YoY to KRW 73.7 billion (2020: 50.3 billion) in the full year of 2021
  • Both full-year and fourth-Quarter unconsolidated revenues (-4.7%/-14.3% YoY) temporary setback due to the expiration of in- license vaccine contracts, however, largely offset by robust prescription drug and its domestic flu vaccine sales
  • Consolidated revenue increased 2.2% YoY, driven by strong growth in consolidated subsidiaries including GC WellBeing (+20.3% YoY) and GC Cell (+96.7% YoY), partially offset by lower revenues in GC Medical Science (-10.3% YoY)
  • Flu Vx sales recorded historical-high sales of +38% YoY, due to rise in N/H Flu Vx export and strong domestic sales performance
  • Weaker sales of international proteins business continued, as a result of balancing inventory control regarding oversea market expansion
  • Despite increased of SG&A cost(+14.5% YoY), gross margin profit growth of 4.6%p due to product portfolio optimization

About GC Pharma

GC Pharma (formerly known as Green Cross Corporation) is a biopharmaceutical company that delivers life-saving and life-sustaining protein therapeutics and vaccines. Headquartered in Yongin, South Korea, GC Pharma is one of the leading plasma protein and vaccine product manufacturers globally and has been dedicated to quality healthcare solutions for more than half a century. Green Cross Corporation updated its corporate brand to GC Pharma in early 2018. Green Cross Corporation remains the company’s legal name.

This press release may contain forward-looking statements, which express the current beliefs and expectations of GC Pharma’s management. Such statements do not represent any guarantee by GC Pharma or its management of future performance and involve known and unknown risks, uncertainties and other factors. GC Pharma undertakes no obligation to update or revise any forward-looking statement contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220214005390/en/

CONTACT

Investor/Media Contact

HyunGoo Kang

gookang@gccorp.com

Yelin Jun

yelin@gccorp.com

Sohee Kim

shkim20@gccorp.com

Hansaem Kim

hs.kim@gccorp.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Genuv Announces Preclinical Data to be Released at Two Medical Conferences in June
  • IntelliCentrics Seeks Strategic Alliance With Taiwanese Health Insurance Providers to Serve Millions of Taiwanese Patients Ensuring They Have Remote Access to Trusted, High Quality Healthcare.
  • 中智全球寻求与台湾医疗保险公司结成战略联盟,为数百万台湾患者提供服务,确保他们能够远程获得可靠及优质的医疗保健服务。
  • Sermo调查显示,今年ASCO的与会肿瘤学家对新的肺癌和乳腺癌研究最感兴趣
  • 訂正・差し替え SCAI 2022 Scientific Meeting で心原性ショックの予後改善に向けた Impella の研究と進歩を大きく紹介